Discover the most talked about and latest scientific content & concepts.

JM Binning, AM Smith, JF Hultquist, CS Craik, N Caretta, MG Campbell, L Burton, F La Greca, MJ McGregor, HM Ta, K Bartholomeeusen, BM Peterlin, NJ Krogan, N Sevillano, Y Cheng and JD Gross
The lentiviral protein Viral Infectivity Factor (Vif) counteracts the antiviral effects of host APOBEC3 (A3) proteins and contributes to persistent HIV infection. Vif targets A3 restriction factors for ubiquitination and proteasomal degradation by recruiting them to a multi-protein ubiquitin E3 ligase complex. Here, we describe a degradation-independent mechanism of Vif-mediated antagonism that was revealed through detailed structure-function studies of antibody antigen-binding fragments (Fabs) to the Vif complex. Two Fabs were found to inhibit Vif-mediated A3 neutralization through distinct mechanisms: shielding A3 from ubiquitin transfer and blocking Vif E3 assembly. Combined biochemical, cell biological and structural studies reveal that disruption of Vif E3 assembly inhibited A3 ubiquitination but was not sufficient to restore its packaging into viral particles and antiviral activity. These observations establish that Vif can neutralize A3 family members in a degradation-independent manner. Additionally, this work highlights the potential of Fabs as functional probes, and illuminate how Vif uses a multi-pronged approach involving both degradation dependent and independent mechanisms to suppress A3 innate immunity.
Facebook likes*
News coverage*
SC clicks
HIV, Protein, Proteasome, Viral infectivity factor, APOBEC3G, Immune system
MeSH headings
comments powered by Disqus

* Data courtesy of